Increased serum IgG antibody response to Merkel cell polyomavirus oncoproteins in patients with autoimmune rheumatic diseases
- 4 June 2025
- journal article
- Published by Oxford University Press (OUP) in International Immunology
Abstract
Autoimmune rheumatic diseases (AIRDs) encompass a spectrum of disorders with a partially understood pathogenesis. A role for polyomaviruses in AIRDs occurrence has been reported. However, the involvement of Merkel cell polyomavirus (MCPyV), the main causative factor of Merkel cell carcinoma (MCC), an aggressive skin neoplasm related to immunosuppression, in AIRDs is unknown. The prevalence/serological profiles of immunoglobulin G (IgG) antibodies to MCPyV large and small T (LT/sT) oncoproteins and viral capsid proteins 1 and 2 (VP1/2) were investigated herein in 540 immunosuppressive treatment-naive AIRD patients, encompassing 447 rheumatoid arthritis (RA) and 93 ankylosing spondylitis (AS) patients by seven MCPyV-specific immunoassays. Control sera from 500 healthy subjects (HS) and 128 MCC patients were included. MCPyV DNA and LT/VP1 mRNAs were evaluated in peripheral blood mononuclear cells (PBMCs) from 75 randomly selected AIRD patients. AIRD patients exhibited higher prevalence and levels (optical densities) of serum anti-oncoprotein IgGs (12%–13%, 0.2–0.6) compared to HS (2%–7%, 0.1–0.4), but lower than MCC patients (70%–83%, 0.2–0.7) (P < .05), with the increase being more pronounced in AS (24%–29%, 0.3–0.8) than in RA (9%–11%, 0.2–0.8) (P < .05). Conversely, similar rates and levels of serum anti-capsid proteins IgGs were determined in most cases between study and control groups (60%–73%, 0.1–0.3) (P > .05). Moreover, receiver operating characteristic (ROC) curves indicated that the MCPyV serology can discriminate AIRD patients from HS (P < .0001). A fraction (11%) of AIRD PBMCs tested MCPyV DNA (7.4 ± 2.6 [copy/104 cells]) and mRNA-positive (0.5–0.1 [1/ΔCt]), while matched sera showed high rates and levels of anti-oncoproteins IgGs (38%–75%, 0.2–2). Our study provides the first evidence that AIRD patients are immunologically responsive to MCPyV oncoproteins, with a fraction of these patients presenting an increased presentation of MCPyV LT and sT antigens, possibly due to viral LT/sT oncogene expression in their PBMCs. These data suggest an association between MCPyV infection and AIRDs pathogenesis.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (21956)
- Fondo di Ateneo per la Ricerca
This publication has 49 references indexed in Scilit:
- Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted TherapiesReviews in Medical Virology, 2024
- Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directionsSeminars in Arthritis and Rheumatism, 2024
- Genetic Approaches to Study Rheumatic Diseases and Its Implications in Clinical PracticeArthritis & Rheumatology, 2024
- Distinct retinoic gene signatures discriminate Merkel cell polyomavirus‐positive from ‐negative Merkel cell carcinoma cellsJournal of Medical Virology, 2023
- Parvovirus B19: Insights and implication for pathogenesis, prevention and therapyAspects of Molecular Medicine, 2023
- Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine developmentMolecular Carcinogenesis, 2020
- The frequency of Merkel cell polyomavirus in whole blood from immunocompetent and immunosuppressed patients with kidney disease and healthy donorsMicrobial Pathogenesis, 2019
- Reactivation of human polyomaviruses in immunocompromised statesJournal of NeuroVirology, 2014
- Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblingsJournal of Clinical Virology, 2013
- Kaposi sarcoma and Merkel cell carcinoma after autoimmune diseaseInternational Journal of Cancer, 2011